News for PEPG Stock

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference PepGen Announces Appointment of Two New Directors to its Board PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference PepGen to Participate in Upcoming Investor Conferences PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1 PepGen Announces CONNECT Program Updates PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights PepGen to Participate in Upcoming Investor Conferences PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications PepGen Announces Executive Team Promotions PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights PepGen to Participate in Upcoming Investor Conferences PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1 PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock Mary Beth DeLena Joins PepGen as General Counsel and Secretary PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1 PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1 PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference PepGen to Participate in the Stifel 2023 CNS Days Conference PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference PepGen to Participate in the SVB Securities Global Biopharma Conference PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments PepGen to Participate in the Stifel 2022 Healthcare Conference PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy PepGen Appoints Habib Dable to Board of Directors PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments PepGen Appoints Caroline Godfrey, Ph.D. to the Company’s Scientific Advisory Board PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments PepGen Announces Pricing of Initial Public Offering